Events
Kubin, Gleave and the ACLU: Are Genes Becoming Unpatentable?
Wednesday, June 24, 2009
7:30 - 8:00 am PDT - Registration and breakfast
8:00 - 9:30 am PDT - Roundtable discussion
McDermott Will & Emery LLP
275 Middlefield Road, Suite 100
Menlo Park, CA 94025
View Map
Summary
The Federal Circuit continues to change the rules for asessing risk and valuation of patents. In its recent Kubin and Gleave decisions, the Federal Circuit has changed the rules for life science and pharmaceutical companies with DNA sequence patents. Perhaps sensing the change of the tide, the ACLU recently filed a lawsuit against Myriad Genetics and other entities asking the court to declare gene patents unconstitutional.
Join McDermott Intellectual Property, Media and Technology partners for an interactive discussion of how these Federal Circuit cases have changed the assessment of gene patents, what the ACLU suit may mean for patenting DNA and other molecules isolated from nature, and how these developments may combine with pending biosimilar legislation to alter the competitive landscape for biological drugs.
McDermott Speakers
William Gaede, Partner, McDermott Will & Emery LLP
David A. Gay, Ph.D., Partner, McDermott Will & Emery LLP
Andrew Kumamoto, Ph.D., Partner, McDermott Will & Emery LLP
Key Cases and Topics
- How has Kubin affected obviousness for gene patents?
- How has Gleave affected anticipation of gene patents in view of the human genome project?
- Will the courts agree with the ACLU that gene patents are unconstitutional?
- Does the ACLU suit pose a threat to the patenting of other molecules isolated from nature?
CLE Accreditation:
CLE credit is pending in California. A Certificate of Attendance will be made available upon request for all other states.
There is no cost to participate in this briefing, but pre-registration is required. For questions about registration, please contact Jill Stolarik at +1 866 705 9676 or jillstolarik@mwe.com.
McDermott Will & Emery's IP Management Roundtables are designed for the educational benefit of a company president, CEO, general counsel or other executive with an interest in intellectual property. Please be advised McDermott has the right to restrict attendance and may limit participation in this event.
